The Animal Core will provide SPORE investigators robust animal models that recapitulate key molecular and histologic phenotypes of human GBM tumors through the development and maintenance of a panel of serially transplantable GBM tumor lines and brain tumor initiating cell (BTIC) that are carefully characterized for key molecular and functional features. These tumor models are more clinically relevant than established cell lines grown as xenografts. This observation has many implications for neuro-oncology research, but is likely to be of greatest importance for testing experimental therapeutics. We believe that testing novel therapeutics regimens in these xenograft and BTIC models will provide more accurate translation of results into clinical efficacy in human trials. During the previous funding cycle, resources provided by this Core were used in 41 peer reviewed publications and were integral components in 8 extramurally funded grant applications. During the current funding period, the Animal Core will continue with 8 key functions: 1. Initiate passage, and archive xenograft tumors and brain tumor initiating cultures (BTIC) from GBM patients 2. Compare tumors derived from BTIC vs. direct xenografting of patient tissue. 3. Provide detailed molecular and functional characterization of each xenograft line. 4. Collect, process, and distribute xenograft and BTIC tumor samples within and beyond the SPORE. 5. Coordinate and conduct in vivo experiments using the xenograft/BTIC panel. 6. Coordinate and conduct imaging studies using the xenograft/BTIC panel. 7. Establish secondary models for therapeutic resistance in select xenograft lines. 8. Maintain up-to-date records on all BTIC cultures, xenograft tissues and related biospecimens. All specimens will be collected and processed under tight quality control, and will be distributed to SPORE researchers or banked for future SPORE research projects. The SPORE Pathology and Tissue Procurement Core will assure that specimens are property fixed, stained, and histologically evaluated. The Clinical Research Core will ensure that patients are property consented for use of their tumor tissues in establishing xenograft tissues and BTICs, will provide clinical outcome for the patients, and will ensure normal tissue samples are collected and archived for potential future studies. Finally, the Biostatistics Core will support statistical analyses and interpretation of the studies performed within the Core.

Public Health Relevance

The development and use of clinically relevant tumor models is essential for successful translation of novel therapeutic strategies into clinical practice. The Animal Core will develop, characterize and use highly relevant xenograft and brain tumor initiating cultures for testing therapeutic strategies within this application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-08
Application #
8567083
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$403,110
Indirect Cost
$149,582
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Oi, N; Yuan, J; Malakhova, M et al. (2015) Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene 34:2660-71
Choi, Jae Won; Schroeder, Mark A; Sarkaria, Jann N et al. (2014) Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res 74:484-96
Bradley, Barrie S; Loftus, Joseph C; Mielke, Clinton J et al. (2014) Differential expression of microRNAs as predictors of glioblastoma phenotypes. BMC Bioinformatics 15:21
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Bell, Michael P; Renner, Danielle N; Johnson, Aaron J et al. (2014) An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. PLoS One 9:e94332
Catteau, Aurélie; Girardi, Hélène; Monville, Florence et al. (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58
Johnson, Holly L; Jin, Fang; Pirko, Istvan et al. (2014) Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption. J Neurovirol 20:107-12
Gupta, Shiv K; Mladek, Ann C; Carlson, Brett L et al. (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-41
Assefnia, Shahin; Dakshanamurthy, Sivanesan; Guidry Auvil, Jaime M et al. (2014) Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget 5:1458-74
Wang, Enfeng; Zhang, Chunyang; Polavaram, Navatha et al. (2014) The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One 9:e86102

Showing the most recent 10 out of 103 publications